🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Throat Carcinoma

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites📍 Santa Rosa📍 Hartford📍 Washington D.C. VM Oncology, LLC · Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus NCT05918510n/a1 site📍 Rome Regina Elena Cancer Institute · Tests: Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy NCT05892354NA20 sites📍 Fuzhou📍 Fuzhou📍 Guangzhou First Affiliated Hospital of Guangxi Medical University · Tests: Enteral immunonutrition, Standard enteral nutrition Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening NCT05447169n/a1 site📍 Guangzhou Sun Yat-sen University · Tests: EBV antibodies test, EBV DNA test Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma NCT04778956Phase 37 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Sun Yat-sen University · Tests: Toripalimab, salvage surgery EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma NCT06802835Phase 1, Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: EGFR Antibody, PD-1 antibody, Gemcitabine, Cisplatin, IMRT GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma NCT06455410Phase 212 sites📍 Foshan📍 Guangzhou📍 Guangzhou Sun Yat-sen University · Tests: GP, Adebrelimab, concurrent chemoradiotherapy (CCRT) Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer NCT06819228Phase 11 site📍 Nashville Vanderbilt-Ingram Cancer Center · Tests: Panitumumab IRDye 800 A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis NCT06308328n/a10 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Nanfang Hospital, Southern Medical University Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer NCT07667400Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: SX-682, DTX 18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma NCT04813705Phase 24 sites📍 Taizhou📍 Taizhou📍 Taizhou Taizhou Hospital · Tests: Reduced dose, Conventional dose, Chemotherapy Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC NCT06752239Phase 31 site📍 Nanchang Jiangxi Provincial Cancer Hospital · Tests: Modified delineation, Standard delineation Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma NCT04425265NA3 sites📍 Guangzhou📍 Zhuhai📍 Nanchang Sun Yat-sen University · Tests: Plasma radiofrequency ablation, Electrocautery block resection Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma NCT03215719Phase 21 site📍 New York NYU Langone Health · Tests: Standard Radiation Treatment, Dose-Deescalated Treatment, Cisplatinum De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas NCT03396718NA10 sites📍 Tübingen📍 Essen📍 Dresden Technische Universität Dresden · Tests: De-escalation radio(chemo)therapy - Level 1, De-escalation radio(chemo)therapy - Level 2, Standard radio(chemotherapy) Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma NCT05717790NA9 sites📍 Baise City📍 Baise City📍 Guilin Fourth Affiliated Hospital of Guangxi Medical University · Tests: Nimotuzumab, Gemcitabine, Cisplatin, Intensity-modulated radiotherapy Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial NCT07340515Phase 31 site📍 Jinan Man Hu · Tests: Intensity-Modulated Proton Therapy (IMPT), Intensity-Modulated Radiation Therapy (IMRT), Cisplatin, Toripalimab Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma NCT07762976Phase 21 site📍 Shanghai Fudan University · Tests: Observation, Adjuvant therapy, Adjuvant therapy PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC NCT07332247Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Selective re-irradiation, Immediate re-irradiation Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases NCT03093909Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Gemcitabine PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients NCT03907826Phase 312 sites📍 Guangzhou📍 Beijing📍 Chengdu Sun Yat-sen University · Tests: PD-1 blocking antibody, GP, IMRT A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC) NCT06829147n/a1 site📍 Guangzhou Sun Yat-sen University TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer NCT06868433Phase 12 sites📍 Atlanta📍 Atlanta Emory University · Tests: Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Res… Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial NCT05340491Phase 312 sites📍 Guangzhou📍 Beijing📍 Chengdu Sun Yat-sen University · Tests: Toripalimab, Chemotherapy, Intensity modulated radiotherapy Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery NCT06747390Phase 11 site📍 Philadelphia Ryan Carey · Tests: Lidocaine 1% Injectable Solution Clinical Treatments in Specialized Diseases of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC) NCT04908696n/a1 site📍 Shanghai Eye & ENT Hospital of Fudan University · Tests: routines The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma NCT05494190NA3 sites📍 Harbin📍 Jinan📍 Shanghai Eye & ENT Hospital of Fudan University · Tests: Docetaxel, Cisplatin, Capecitabine, Concomitant chemoradiotherapy, Surgery Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC NCT06197776n/a1 site📍 Guangzhou Sun Yat-sen University · Tests: cisplatin-based chemoradiotherapy combined with immunotherapy LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC NCT07325539Phase 22 sites📍 Guangzhou📍 Shenzhen Sun Yat-sen University · Tests: Gemcitabine(GEM), Cisplatin, Toripalimab, LDRT Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC NCT05854849Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Camrelizumab, Gemcitabine, Cisplatin, Apatinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy